Lucas Montarce

We have a very thorough process and we feel good about the guide that we have in place for 2026.

It's still very compelling, by the way.

25%, there is no single pharma company growing at this pace.

So we feel a bit about good.

We can see throughout the year if we see that continue to trend in the positive direction.

But at this time, given all the variables that we have, we feel good about the guide that we have in place.

At this time, we are engaging with the FDA, and we feel good about the progress.

And so the time that I covered in JP Morgan that you alluded is still consistent with our expectation that we expect to see regulatory action as early as Q2.

Yeah, well, actually the guide, 25%, is encompassing as well the price step up or step down that we have in 2026.

So that's included in our guide for 2026 already.

When you think about the valuables, they are all actually out there.

We talk about the agreement with the administration.

Those prices are public.

We talk about direct to patient that we adjust the price by $50 across all our presentations.

That's actually already implemented in the marketplace as of last December.

And then we have the Medicare access that, again, we have a price of $245.

That's also public price, public information out there as well.

So those variables are out there.

There is no news from my perspective in terms of the pricing dynamics.

It's still going to be a price erosion versus last year.